Mabion S.A.

Konstantynów Łódźki, Poland
Monoclonal Antibody Recombinant Protein Biosimilars Vaccine Antigens ADC / PDC (analytics & development) Sterile Fill-Finish
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (2) ○ EMA GMP ○ MHRA GMP

Quick Facts: Mabion S.A.

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Konstantynów Łódźki, Poland
Modalities
Monoclonal Antibody, Recombinant Protein, Biosimilars, Vaccine Antigens, ADC / PDC (analytics & development), Sterile Fill-Finish
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Mabion S.A.

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Recombinant Protein, Biosimilars, Vaccine Antigens, ADC / PDC (analytics & development), Sterile Fill-Finish
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (6 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press2 articles
Broad modality coverage (6 modalities)

Recent News 2 articles

news Tue, 10 Fe
Women in STEM: Unique Impacts in Rare Disease Development - PharmTech.com
Source →
news Mon, 30 Ju
Mabion, NovalGen Partner to Bring NVG-222 to Market - Contract Pharma
Source →

Frequently Asked Questions About Mabion S.A.

What is Mabion S.A.'s CDMO Signal Score?
Mabion S.A. has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Mabion S.A. for a manufacturing program?
Use the free AI matchmaker to compare Mabion S.A. against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Recombinant Protein CDMOs → ADC / PDC (analytics & development) CDMOs →

Similar CDMOs

EirGenix
Zhubei City, Hsinchu County, Taiwan
Monoclonal Antibody, Bispecific/Polyclonal Antibody, Recombinant Protein, ADC, Biosimilars, Plasmid DNA
KBI Biopharma
Durham, NC · Boulder, CO
Signal Score: 83.5
Monoclonal Antibody, Recombinant Protein, AAV, Plasmid DNA
Rentschler Biopharma
Laupheim, Germany
Signal Score: 79.9
Monoclonal Antibody, Recombinant Protein
Catalent
Bagsværd, Denmark (operating under Novo Holdings)
Signal Score: 76.5
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
Signal Score: 75.1
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish